Table 4. In Vitro Antiproliferative Activity of Compound 1 and the Anticancer Drug Doxorubicin against Human Prostate Cancer (PC-3), Hepatocellular Carcinoma (HEPG-2), Colorectal Carcinoma (HCT-116), Mammary Gland Breast Cancer (MCF-7), and Epithelioid Carcinoma (HeLa) Cell Lines.
| IC50 (μM)a |
|||||
|---|---|---|---|---|---|
| PC-3 | HEPG-2 | HCT-116 | MCF-7 | HeLa | |
| compound 1 | 41.75 ± 2.9 | 16.38 ± 1.5 | 29.55 ± 2.2 | 9.32 ± 0.7 | 7.18 ± 0.5 |
| doxorubicin | 8.87 ± 0.6 | 4.50 ± 0.2 | 5.23 ± 0.3 | 4.17 ± 0.2 | 5.57 ± 0.4 |
a
IC50 values presented as the mean ± SD of three separate determinations, p < 0.05.